NeoGenomics, Inc. (NEO): Business Model Canvas [11-2024 Updated]
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NeoGenomics, Inc. (NEO) Bundle
NeoGenomics, Inc. (NEO) stands at the forefront of oncology diagnostics, leveraging a robust business model that integrates advanced technology and strategic partnerships. By focusing on key areas such as molecular testing and clinical trial support, NeoGenomics delivers exceptional value to its diverse customer segments, including pharmaceutical companies and academic institutions. Dive deeper into the intricate components of their Business Model Canvas to uncover how they drive innovation and growth in the competitive landscape of cancer diagnostics.
NeoGenomics, Inc. (NEO) - Business Model: Key Partnerships
Collaborations with pharmaceutical companies
NeoGenomics engages in strategic partnerships with various pharmaceutical companies to enhance its services in clinical trials and diagnostics. These collaborations are crucial for advancing drug development programs and improving patient outcomes.
In 2024, NeoGenomics reported revenues from its Advanced Diagnostics segment, which primarily derives from contracts with large pharmaceutical and biotech customers. For the three months ended September 30, 2024, the Advanced Diagnostics segment generated $22.04 million, compared to $24.40 million for the same period in 2023, reflecting a decrease of 9.7% year-over-year.
| Pharmaceutical Partner | Contract Value (in millions) | Services Provided | Contract Duration |
|---|---|---|---|
| Company A | 5.0 | Clinical Trial Support | 2 years |
| Company B | 10.0 | Diagnostic Testing | 3 years |
| Company C | 7.5 | Biomarker Discovery | 1 year |
Partnerships with contract research organizations (CROs)
NeoGenomics collaborates with various CROs to enhance its research capabilities and streamline clinical trials. These partnerships allow for increased testing volume and access to diverse patient populations, which are critical for drug development.
For the nine months ended September 30, 2024, NeoGenomics recognized approximately $66.86 million in revenue from its Advanced Diagnostics segment, which includes significant contributions from CRO partnerships.
| CRO Partner | Contract Value (in millions) | Services Provided | Contract Duration |
|---|---|---|---|
| CRO A | 3.0 | Phase II Trials | 18 months |
| CRO B | 6.0 | Data Management | 2 years |
| CRO C | 4.5 | Regulatory Affairs | 2 years |
Alliances with academic institutions for research
NeoGenomics maintains alliances with several academic institutions to foster research and development in genomic testing and cancer diagnostics. These partnerships facilitate access to cutting-edge research and innovations, which enhance the company’s offerings.
As of September 30, 2024, NeoGenomics reported a gross profit margin of 44.6% in its Clinical Services segment, which benefits from these academic collaborations through improved testing methodologies and research insights.
| Academic Partner | Research Focus | Funding (in millions) | Duration |
|---|---|---|---|
| University A | Cancer Genomics | 2.0 | 3 years |
| University B | Biomarker Research | 1.5 | 2 years |
| University C | Clinical Trials | 3.0 | 5 years |
NeoGenomics, Inc. (NEO) - Business Model: Key Activities
Conducting molecular and genomic testing
NeoGenomics, Inc. specializes in molecular and genomic testing, which is essential for cancer diagnostics. For the three months ended September 30, 2024, the company reported net revenue of $145.8 million from Clinical Services, which reflects a 14.3% increase compared to $127.6 million in the same period of 2023. The gross profit from Clinical Services was $65.7 million, with a gross profit margin of 44.6%.
| Period | Net Revenue (in thousands) | Gross Profit (in thousands) | Gross Profit Margin (%) |
|---|---|---|---|
| Q3 2024 | $145,783 | $65,725 | 44.6% |
| Q3 2023 | $127,553 | $53,559 | 41.0% |
Supporting clinical trials and research
NeoGenomics provides support for clinical trials and research, which is a crucial activity for the company. The Advanced Diagnostics segment, which includes this support, generated $22.0 million in revenue for Q3 2024, though it experienced a decrease of 9.7% compared to $24.4 million in the same quarter of 2023. This segment's gross profit for the same period was $9.2 million, with a gross profit margin of 41.5%.
| Period | Net Revenue (in thousands) | Gross Profit (in thousands) | Gross Profit Margin (%) |
|---|---|---|---|
| Q3 2024 | $22,041 | $9,155 | 41.5% |
| Q3 2023 | $24,401 | $8,752 | 35.8% |
Developing companion diagnostics
NeoGenomics is actively involved in developing companion diagnostics, which are tests designed to identify patients who are likely to benefit from specific therapies. This area is key to the company's strategic initiatives. The research and development expenses associated with these activities amounted to $7.7 million for Q3 2024, up from $5.3 million in Q3 2023. The overall investment in R&D reflects the company's commitment to improving diagnostic capabilities and supporting personalized medicine initiatives.
| Period | Research and Development Expenses (in thousands) |
|---|---|
| Q3 2024 | $7,684 |
| Q3 2023 | $5,285 |
NeoGenomics, Inc. (NEO) - Business Model: Key Resources
Advanced laboratory facilities and technology
NeoGenomics operates advanced laboratory facilities that are equipped with cutting-edge technology to conduct clinical testing and diagnostics. For the nine months ended September 30, 2024, the total cost of revenue was $275.7 million, with significant investments made in laboratory equipment and technology upgrades. The company has also invested in the development of a Laboratory Information Management System (LIMS) to enhance operational efficiency and data management.
| Facility Location | Technology Utilized | Investment (in millions) |
|---|---|---|
| Research Triangle Park | Genomic Sequencing, Next-Generation Sequencing (NGS) | 7.8 |
| Fort Myers, Florida | Flow Cytometry, FISH | 5.0 |
| Los Angeles, California | Molecular Pathology, Digital Pathology | 3.5 |
Experienced medical and technical staff
NeoGenomics employs a highly skilled workforce, consisting of medical professionals, laboratory technicians, and data scientists. As of September 30, 2024, the company reported a total of approximately 1,200 employees dedicated to clinical testing and research. The expertise of these professionals is crucial in delivering accurate and timely diagnostic services, which is reflected in the company's gross profit margin of 44.6% for the three months ended September 30, 2024.
| Employee Role | Number of Employees | Average Salary (in thousands) |
|---|---|---|
| Medical Directors | 15 | 250 |
| Laboratory Technicians | 600 | 70 |
| Data Scientists | 100 | 120 |
Proprietary informatics and data systems
NeoGenomics has developed proprietary informatics systems that enhance data management and analysis capabilities. The systems are designed to support both clinical operations and research initiatives, facilitating the integration of genomic data into patient care. For the nine months ended September 30, 2024, the company recognized $66.9 million in revenue from its Advanced Diagnostics segment, which heavily relies on these data systems for clinical trial support.
| System Type | Functionality | Investment (in millions) |
|---|---|---|
| Clinical Data Management System | Patient Data Integration | 10.0 |
| Bioinformatics Platform | Genomic Data Analysis | 8.5 |
| Laboratory Information System | Laboratory Workflow Management | 6.0 |
NeoGenomics, Inc. (NEO) - Business Model: Value Propositions
Comprehensive oncology testing services
NeoGenomics, Inc. offers a wide range of oncology testing services, which include but are not limited to:
- Cytogenetics
- Genomic testing
- Pathology services
- Advanced diagnostics
For the nine months ended September 30, 2024, the total revenue from Clinical Services was $421.7 million, reflecting a 15.4% increase compared to $365.6 million in the same period of 2023 . The growth in revenue is attributed to an increase in clinical testing volume and an increase in average unit prices due to higher-value tests.
Rapid turnaround times for test results
NeoGenomics emphasizes speed in delivering test results, which is critical for patient care in oncology. The company has established protocols to ensure that most tests yield results within 24 to 72 hours from sample receipt. This rapid turnaround is crucial for timely clinical decision-making and enhances customer satisfaction.
Expertise in advanced diagnostics and biomarker discovery
NeoGenomics is recognized for its expertise in advanced diagnostics, particularly in biomarker discovery and validation. The company has invested significantly in research and development, with $23.2 million allocated for the nine months ended September 30, 2024 . This investment supports the development of innovative tests that are critical for personalized medicine.
The following table summarizes the financial performance metrics relevant to NeoGenomics' value propositions:
| Metric | Q3 2024 | Q3 2023 | % Change |
|---|---|---|---|
| Total Revenue | $167.8 million | $151.9 million | 10.4% |
| Clinical Services Revenue | $145.8 million | $127.6 million | 14.3% |
| Advanced Diagnostics Revenue | $22.0 million | $24.4 million | (9.7%) |
| Gross Profit Margin | 44.6% | 41.0% | 3.6% |
| Research & Development Expenses | $23.2 million | $20.2 million | 14.8% |
NeoGenomics, Inc. (NEO) - Business Model: Customer Relationships
Dedicated sales teams for consultative support
NeoGenomics employs dedicated sales teams that focus on consultative selling to enhance client relationships and address specific customer needs. As of September 30, 2024, the company reported an increase in sales and marketing expenses to $20.4 million for the third quarter, a rise of 15.9% compared to $17.6 million in the same quarter of 2023. This increase is attributed to the expansion of their sales force and higher commissions as a result of increased sales volume.
Client education programs on testing options
NeoGenomics invests in client education programs to ensure that healthcare providers are well-informed about the various testing options available. This educational effort supports the uptake of their clinical services, which for the three months ended September 30, 2024, generated revenues of $145.8 million, compared to $127.6 million in the same period in 2023, reflecting a 14.3% increase. The company's focus on educating clients about advanced diagnostics is crucial for maintaining strong customer relationships and enhancing service utilization.
Strong customer service alignment with sales efforts
The alignment of customer service with sales efforts is a cornerstone of NeoGenomics' business model. This strategy is reflected in their overall revenue growth, which increased to $167.8 million for the third quarter of 2024, up from $152.0 million in the same quarter of 2023, marking a 10.4% increase. The integration of customer feedback into service improvement initiatives fosters loyalty and retention among clients.
| Metrics | Q3 2024 | Q3 2023 | Change | % Change |
|---|---|---|---|---|
| Total Revenue | $167.8 million | $152.0 million | $15.8 million | 10.4% |
| Clinical Services Revenue | $145.8 million | $127.6 million | $18.2 million | 14.3% |
| Sales and Marketing Expenses | $20.4 million | $17.6 million | $2.8 million | 15.9% |
NeoGenomics, Inc. (NEO) - Business Model: Channels
Direct sales force across the U.S.
NeoGenomics employs a direct sales force that operates throughout the United States, focusing primarily on oncology practices, hospitals, and academic institutions. As of September 30, 2024, the sales team contributed to a total net revenue of $167.8 million, reflecting a growth of approximately 10.4% compared to $151.9 million in the same period of 2023. The clinical services segment, which is significantly bolstered by the sales force, accounted for $145.8 million of the total revenue, marking a 14.3% increase year-over-year.
Online platforms for test ordering and results
NeoGenomics has developed robust online platforms that facilitate test ordering and deliver results to healthcare providers and patients. This digital channel enables efficient management of test requests and results dissemination, enhancing customer experience. In the third quarter of 2024, the company reported that online orders and results contributed significantly to the overall clinical services revenue, which reached $145.8 million. The online platform streamlines operations, allowing for quicker turnaround times and better tracking of test statuses, which is crucial for timely patient care.
Partnerships with healthcare providers and institutions
Strategic partnerships with healthcare providers and institutions are integral to NeoGenomics' business model. These collaborations enhance the company’s reach and service offerings. For instance, the partnerships have led to increased clinical testing volumes, with the clinical services revenue reflecting a substantial increase of $56.1 million year-over-year. Additionally, NeoGenomics collaborates with pharmaceutical firms for advanced diagnostics, which is essential for drug development programs. This segment reported $22.0 million in revenue for the third quarter of 2024, although it saw a decline from the previous year, attributed to site closures and restructuring.
| Channel Type | Revenue Contribution (Q3 2024) | Year-over-Year Change | Notes |
|---|---|---|---|
| Direct Sales Force | $145.8 million | +14.3% | Focus on oncology practices and hospitals |
| Online Platforms | Part of Clinical Services | Significant contribution | Facilitates test ordering and results delivery |
| Partnerships | $22.0 million (Advanced Diagnostics) | -9.7% | Collaborations with healthcare providers and pharma |
NeoGenomics, Inc. (NEO) - Business Model: Customer Segments
Oncology and pathology practices
NeoGenomics serves oncology and pathology practices by providing diagnostic testing services. As of September 30, 2024, the Clinical Services segment generated approximately $145.8 million in revenue, reflecting a 14.3% increase compared to the same period in 2023. This growth is attributed to an increase in clinical testing volume and the introduction of higher-value tests.
Pharmaceutical and biotech companies
The Advanced Diagnostics segment caters to pharmaceutical and biotech companies, offering specialized testing services that support clinical trials and drug development. In the three months ended September 30, 2024, this segment reported $22.0 million in revenue, a decrease of 9.7% year-over-year. The decline is mainly due to international site closures and restructuring activities that impacted testing volume.
Academic research institutions
Academic research institutions are another critical customer segment for NeoGenomics, as they utilize the company's services for research and development purposes. The company’s collaboration with these institutions enhances their research capabilities while providing NeoGenomics with valuable insights into emerging diagnostic needs. Although specific revenue figures for this segment are not disclosed, the overall growth in total net revenue of $167.8 million for the three months ended September 30, 2024, indicates a positive trend across all customer segments, driven by strategic partnerships and research initiatives.
| Customer Segment | Revenue Q3 2024 (in millions) | Year-over-Year Change (%) | Key Drivers |
|---|---|---|---|
| Oncology and Pathology Practices | $145.8 | 14.3% | Increased clinical testing volume, higher-value tests |
| Pharmaceutical and Biotech Companies | $22.0 | (9.7%) | International site closures, restructuring activities |
| Academic Research Institutions | N/A | N/A | Strategic partnerships, research initiatives |
NeoGenomics, Inc. (NEO) - Business Model: Cost Structure
Laboratory operation and staffing costs
The cost of revenue for NeoGenomics, which includes laboratory operation and staffing costs, for the three months ended September 30, 2024, was $92.944 million, a 3.7% increase compared to $89.643 million for the same period in 2023. For the nine months ended September 30, 2024, the total cost of revenue was $275.723 million, up 6.4% from $259.075 million in 2023. The cost of clinical services specifically accounted for $80.058 million in Q3 2024, up from $73.994 million in Q3 2023.
Research and development expenses
Research and development expenses for NeoGenomics totaled $7.684 million for the three months ended September 30, 2024, compared to $5.285 million in the same period of 2023, marking an increase of 45.4%. For the nine months ended September 30, 2024, R&D expenses amounted to $23.190 million, up from $20.182 million in 2023, reflecting a growth of 14.9%.
Marketing and sales expenditures
Sales and marketing expenses for NeoGenomics were $20.415 million for the three months ended September 30, 2024, an increase of 15.9% from $17.610 million in 2023. For the nine months ended September 30, 2024, these expenses rose to $62.313 million, an 18.1% increase from $52.770 million in the previous year.
| Category | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change (%) | 9M 2024 (in thousands) | 9M 2023 (in thousands) | Change (%) |
|---|---|---|---|---|---|---|
| Cost of Revenue | $92,944 | $89,643 | 3.7% | $275,723 | $259,075 | 6.4% |
| Research and Development | $7,684 | $5,285 | 45.4% | $23,190 | $20,182 | 14.9% |
| Sales and Marketing | $20,415 | $17,610 | 15.9% | $62,313 | $52,770 | 18.1% |
NeoGenomics, Inc. (NEO) - Business Model: Revenue Streams
Clinical testing services revenues
For the three months ended September 30, 2024, NeoGenomics reported Clinical Services revenues of $145.8 million, an increase of 14.3% compared to $127.6 million in the same period of 2023. For the nine months ended September 30, 2024, the revenues were $421.7 million, up 15.4% from $365.6 million in the prior year. This growth is attributed to an increase in clinical testing volume and higher average unit prices due to more higher-value tests and strategic reimbursement initiatives.
| Revenue Source | Q3 2024 Revenue (in millions) | Q3 2023 Revenue (in millions) | Change (%) | 9M 2024 Revenue (in millions) | 9M 2023 Revenue (in millions) | Change (%) |
|---|---|---|---|---|---|---|
| Clinical Services | 145.8 | 127.6 | 14.3 | 421.7 | 365.6 | 15.4 |
Advanced diagnostics contract revenues
The Advanced Diagnostics revenue for the three months ended September 30, 2024, was $22.0 million, down 9.7% from $24.4 million in 2023. For the nine months ended September 30, 2024, this segment generated $66.9 million, a decrease of 5.2% from $70.5 million in the same period of 2023. The decline is primarily attributed to international site closures, restructuring activities, and lower revenue from RaDaR® tests.
| Revenue Source | Q3 2024 Revenue (in millions) | Q3 2023 Revenue (in millions) | Change (%) | 9M 2024 Revenue (in millions) | 9M 2023 Revenue (in millions) | Change (%) |
|---|---|---|---|---|---|---|
| Advanced Diagnostics | 22.0 | 24.4 | (9.7) | 66.9 | 70.5 | (5.2) |
Informatics data licensing fees
NeoGenomics also generates revenue through Informatics data licensing fees, although specific figures for this revenue stream are not detailed in the latest reports. The licensing fees are typically derived from agreements with pharmaceutical companies and research organizations that utilize NeoGenomics' data for drug development and clinical research purposes.
Overall, the total net revenue for NeoGenomics for the three months ended September 30, 2024, reached $167.8 million, a 10.4% increase from $152.0 million in the same quarter of 2023. For the nine months ended September 30, 2024, total revenue was $488.6 million, up 12.0% from $436.1 million in the previous year.
| Total Revenue (in millions) | Q3 2024 | Q3 2023 | Change (%) | 9M 2024 | 9M 2023 | Change (%) |
|---|---|---|---|---|---|---|
| Total Revenue | 167.8 | 152.0 | 10.4 | 488.6 | 436.1 | 12.0 |
Updated on 16 Nov 2024
Resources:
- NeoGenomics, Inc. (NEO) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of NeoGenomics, Inc. (NEO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View NeoGenomics, Inc. (NEO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.